/C O R R E C T I O N -- Rosetta Gen...(IABILITIES: Short-term bank loan curr...)
| HOME >> BIOLOGY >> TECHNOLOGY |
IABILITIES:
Short-term bank loan, current maturities
of capital lease and of long-term loan $ 168 $ 247
Trade payables 797 516
Other accounts payable and accruals 1,099 1,102
Total current liabilities 2,064 1,865
LONG-TERM LIABILITIES:
Long-term bank loan and capital lease 50 16
Deferred revenue 228 228
Accrued severance pay 366 324
Total Long-term Liabilities 644 568
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS' EQUITY:
Share capital: 27 27
Additional paid-in capital 59,201 58,984
Other comprehensive income 28 86
Deficit accumulated during the
development stage (39,370) (35,492)
Total shareholders' equity 19,886 23,605
Total liabilities and shareholders'
equity $ 22,594 $ 26,038
ROSETTA GENOMICS LTD. AND ITS SUBSIDIARY
(A development stage company)
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
Three months
Year ended December 31, ended March 31,
2007 2006 2008 2007
Unaudited
Operating expenses:
Research and development, net $ 6,400 $ 4
'/>"/>
| SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |